Paul C Nathan, Cindy Lau, Vicky L Ng, Mar Miserachs, Chia Wei Teoh, Melinda Solomon, Anne I Dipchand, Maria Locke, Sumit Gupta
{"title":"儿童、青少年和青年癌症幸存者实体器官移植后的预后:一项基于人群的研究","authors":"Paul C Nathan, Cindy Lau, Vicky L Ng, Mar Miserachs, Chia Wei Teoh, Melinda Solomon, Anne I Dipchand, Maria Locke, Sumit Gupta","doi":"10.1093/jnci/djaf106","DOIUrl":null,"url":null,"abstract":"Background Cancer treatment can lead to organ toxicity requiring solid organ transplant (SOT). Transplant teams must evaluate the appropriateness of SOT in survivors of childhood, or adolescent/young adult (AYA) cancer. Methods Children treated at a provincial (Ontario, Canada) pediatric center for any cancer between 1986-2021, and AYA (15-21 years) treated in an adult center for four common cancer types between 1992-2012, were identified using population-based databases. Outcomes were determined by linkage to administrative databases. Transplanted cancer survivors (cases) were matched 1:2 to SOT recipients without a prior cancer (controls). Post-SOT overall survival (OS), subsequent cancers, severe cardiovascular disease and graft loss/death were compared between groups. Results Among 16,533 cancer survivors, 52 received a SOT: 13 liver, 18 kidney, 11 lung, and 10 heart. Median age at SOT was 18 (IQR 14-27). Transplanted cancer survivors experienced lower 10-year post-SOT OS than controls (67.7 vs. 86.0%; p = 0.003). 10-year cumulative incidence of developing another de novo malignancy was 8.6%, similar to the incidence of first cancers among controls (12.9%; HR 1.05, p = 0.91). 10-year cumulative incidence of primary cancer recurrence was 10.5%. Cases (excluding heart transplants) were at risk for graft loss/death (HR = 2.00, 95% confidence interval 1.01-3.94), but not severe cardiovascular disease (HR = 1.10, CI 0.50-2.41). Conclusion Survivors treated with SOT had inferior survival than SOT recipients without a cancer history, but most achieved long-term cancer-free survival. These data can inform decisions around the suitability of cancer survivors for SOT.","PeriodicalId":501635,"journal":{"name":"Journal of the National Cancer Institute","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes after solid organ transplantation in survivors of childhood, adolescent and young adult cancer: A population-based study\",\"authors\":\"Paul C Nathan, Cindy Lau, Vicky L Ng, Mar Miserachs, Chia Wei Teoh, Melinda Solomon, Anne I Dipchand, Maria Locke, Sumit Gupta\",\"doi\":\"10.1093/jnci/djaf106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Cancer treatment can lead to organ toxicity requiring solid organ transplant (SOT). Transplant teams must evaluate the appropriateness of SOT in survivors of childhood, or adolescent/young adult (AYA) cancer. Methods Children treated at a provincial (Ontario, Canada) pediatric center for any cancer between 1986-2021, and AYA (15-21 years) treated in an adult center for four common cancer types between 1992-2012, were identified using population-based databases. Outcomes were determined by linkage to administrative databases. Transplanted cancer survivors (cases) were matched 1:2 to SOT recipients without a prior cancer (controls). Post-SOT overall survival (OS), subsequent cancers, severe cardiovascular disease and graft loss/death were compared between groups. Results Among 16,533 cancer survivors, 52 received a SOT: 13 liver, 18 kidney, 11 lung, and 10 heart. Median age at SOT was 18 (IQR 14-27). Transplanted cancer survivors experienced lower 10-year post-SOT OS than controls (67.7 vs. 86.0%; p = 0.003). 10-year cumulative incidence of developing another de novo malignancy was 8.6%, similar to the incidence of first cancers among controls (12.9%; HR 1.05, p = 0.91). 10-year cumulative incidence of primary cancer recurrence was 10.5%. Cases (excluding heart transplants) were at risk for graft loss/death (HR = 2.00, 95% confidence interval 1.01-3.94), but not severe cardiovascular disease (HR = 1.10, CI 0.50-2.41). Conclusion Survivors treated with SOT had inferior survival than SOT recipients without a cancer history, but most achieved long-term cancer-free survival. These data can inform decisions around the suitability of cancer survivors for SOT.\",\"PeriodicalId\":501635,\"journal\":{\"name\":\"Journal of the National Cancer Institute\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the National Cancer Institute\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jnci/djaf106\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jnci/djaf106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
癌症治疗可能导致器官毒性,需要实体器官移植(SOT)。移植团队必须评估SOT在儿童或青少年/青年(AYA)癌症幸存者中的适用性。方法使用基于人群的数据库确定1986-2021年间在加拿大安大略省(Ontario, Canada)儿科中心接受任何癌症治疗的儿童,以及1992-2012年间在成人中心接受四种常见癌症类型治疗的AYA(15-21岁)。结果通过与管理数据库的连接来确定。移植癌症幸存者(病例)与没有既往癌症的SOT接受者(对照组)1:2匹配。两组间比较sot后总生存期(OS)、继发癌症、严重心血管疾病和移植物损失/死亡。结果在16533名癌症幸存者中,52名接受了SOT: 13名肝脏,18名肾脏,11名肺部和10名心脏。SOT的中位年龄为18岁(IQR 14-27)。移植癌幸存者经历的10年sot后OS低于对照组(67.7% vs 86.0%;P = 0.003)。10年累积发生另一种新发恶性肿瘤的发生率为8.6%,与对照组中首次癌症的发生率相似(12.9%;HR 1.05, p = 0.91)。原发癌10年累计复发率为10.5%。病例(不包括心脏移植)有移植物丢失/死亡的风险(HR = 2.00, 95%可信区间1.01-3.94),但没有严重的心血管疾病(HR = 1.10, CI 0.50-2.41)。结论接受SOT治疗的幸存者生存率低于无癌症史的SOT接受者,但大多数获得了长期无癌生存。这些数据可以为癌症幸存者是否适合SOT的决定提供信息。
Outcomes after solid organ transplantation in survivors of childhood, adolescent and young adult cancer: A population-based study
Background Cancer treatment can lead to organ toxicity requiring solid organ transplant (SOT). Transplant teams must evaluate the appropriateness of SOT in survivors of childhood, or adolescent/young adult (AYA) cancer. Methods Children treated at a provincial (Ontario, Canada) pediatric center for any cancer between 1986-2021, and AYA (15-21 years) treated in an adult center for four common cancer types between 1992-2012, were identified using population-based databases. Outcomes were determined by linkage to administrative databases. Transplanted cancer survivors (cases) were matched 1:2 to SOT recipients without a prior cancer (controls). Post-SOT overall survival (OS), subsequent cancers, severe cardiovascular disease and graft loss/death were compared between groups. Results Among 16,533 cancer survivors, 52 received a SOT: 13 liver, 18 kidney, 11 lung, and 10 heart. Median age at SOT was 18 (IQR 14-27). Transplanted cancer survivors experienced lower 10-year post-SOT OS than controls (67.7 vs. 86.0%; p = 0.003). 10-year cumulative incidence of developing another de novo malignancy was 8.6%, similar to the incidence of first cancers among controls (12.9%; HR 1.05, p = 0.91). 10-year cumulative incidence of primary cancer recurrence was 10.5%. Cases (excluding heart transplants) were at risk for graft loss/death (HR = 2.00, 95% confidence interval 1.01-3.94), but not severe cardiovascular disease (HR = 1.10, CI 0.50-2.41). Conclusion Survivors treated with SOT had inferior survival than SOT recipients without a cancer history, but most achieved long-term cancer-free survival. These data can inform decisions around the suitability of cancer survivors for SOT.